Randomised, crossover study comparing the Bioavailability of single doses of 186 µg and 372 µg of OPTINOSE FLUTICASONE (intranasal spray) with 400 µg of Flonase (Fluticasone Propionate) Nasal Spray (Part 1)

Trial Profile

Randomised, crossover study comparing the Bioavailability of single doses of 186 µg and 372 µg of OPTINOSE FLUTICASONE (intranasal spray) with 400 µg of Flonase (Fluticasone Propionate) Nasal Spray (Part 1)

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Fluticasone propionate (Primary)
  • Indications Asthma
  • Focus Pharmacokinetics
  • Most Recent Events

    • 04 Apr 2017 New trial record
    • 06 Mar 2017 Results of Part I and Part II studies assessing bioavailability of FLU-EDS, presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top